Tentative trial dates set for four teens charged with murder | SaltWire #newsupdate #halifax #courtLONDON - Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk, said on Wednesday it would buy a controlling stake of about 60% in Single Use Support, an Austria-based life science tools company.
Novo Holdings CEO Kasim Kutay told Reuters in October that the huge Wegovy windfall would increase the size of deals it would do in healthcare, particularly for well-established life-science companies.Novo Holdings said the acquisition was part of its focus on companies that provide services to the pharmaceuticals industry.
Single Use Support, founded in 2017, makes equipment and consumables to support the production of drugs, in particular biologic medicines, cell and gene therapies, and mRNA vaccines.Single Use Support"got a huge boost" from business from Moderna during the COVID-19 pandemic, Johan Hueffer, senior partner in principal investments at Novo Holdings told Reuters.